AEON Biopharma, Inc.
AEONAEON Biopharma, Inc. is a biotechnology company focused on developing targeted therapies for neurological and neurodegenerative disorders. The company aims to advance innovative treatments through rigorous research and clinical development, primarily targeting unmet medical needs in areas such as multiple sclerosis, stroke, and other brain-related conditions.
Company News
AEON Biopharma announced the grant of 392,158 restricted stock units to newly hired non-executive employees on December 11, 2025, under its 2025 Inducement Incentive Plan. The RSUs vest over four years with 25% vesting annually. The company continues development of ABP-450, a BOTOX biosimilar targeting the $3 billion U.S. therapeutic neurotoxin m...
The migraine therapeutics market is experiencing strong growth, with over 30 companies developing innovative treatments targeting migraine through advanced therapies like CGRP inhibitors and gepants, supported by improved diagnostic recognition and patient awareness.
AEON Biopharma, a clinical-stage biopharmaceutical company, announced the closing of a $20 million public offering. The company plans to use the proceeds for general corporate purposes and working capital.
AEON Biopharma, a clinical-stage biopharmaceutical company, announced a public offering of shares and warrants to raise funds for general corporate and working capital needs.
Match Group shares jumped 8% in pre-market trading after Starboard Value took a stake of over 6.5% in the company and is advocating for a potential sale. Several other stocks also saw significant pre-market movement.
